ORIGINAL CONTRIBUTIONS

STUDY OF LEUKOCYTIC HYDROLYTIC ENZYMES IN PATIENTS WITH ACUTE STAGE OF CORONARY HEART DISEASE

VISHWAS CHAVAN, NEELA PATIL, N. D. KARNIK*

ABSTRACT

BACKGROUND: Coronary heart disease (CHD) is a major killer worldwide. Atherosclerosis, which is the basis of CHD, is believed to be an inflammatory disorder. Though various aspects of atherosclerosis are extensively studied, leukocytic hydrolytic enzymes are not studied very well with respect to CHD. AIM: This study was planned to assess changes associated with leukocytic hydrolases in CHD patients. SETTING AND DESIGN: A tertiary care hospital; case-control study. MATERIALS AND METHODS: 106 patients with acute myocardial infarction, 60 patients with unstable angina and 45 healthy controls were included in the study. Acid phosphatase, lysozyme, adenosine deaminase (ADA) and cathepsin-G levels were estimated from leukocytes. Reduced glutathione (GSH) and malondialdehyde (MDA) levels were measured. STATISTICAL ANALYSIS: Statistical comparison of data was done using student's t-test (unpaired). Correlation difference was calculated by using Pearson correlation coefficient. RESULTS: Significantly higher levels of acid phosphatase, lysozyme, ADA with lower levels of cathepsin G in leukocytes were observed in CHD group. We also found significantly higher levels of serum MDA with lower concentrations of blood GSH in CHD group. In diabetic CHD group, significantly higher levels of leukocytic acid phosphatase, lysozyme, ADA and serum MDA with lower levels of cathepsin G and blood GSH were observed. CONCLUSIONS: Our study indicates that leukocyte hydrolytic enzymes, mainly acid phosphatase, lysozyme and ADA were more active in CHD patients and may contribute to inflammation related with CHD. Its also indicates that leukocyte cathepsin-G may have antiinflammatory role.

Keywords: Coronary heart disease, hydrolytic enzymes, inflammation, leukocytes

INTRODUCTION

Atherosclerosis, which is the basis of coronary heart disease (CHD), is believed to be an inflammatory disorder. Inflammation must smolder for decades before resulting in a clinical event like angina or acute myocardial infarction (AMI).  

Generation of free radicals and oxidative stress may have an important role in atherogenesis.

In inflammation, leucocytes rapidly produce free radicals. If free radicals remain in the body for longer time, they can damage body cells. AMI is frequently associated with leukocytosis and an elevated peripheral neutrophil count. It was shown that stimulated leucocytes can modify LDL, which can contribute to atherogenesis.

Also, many risk factors of CHD like diabetes mellitus have relation with inflammation.

One link between inflammation and the incidence of type 2 diabetes may be insulin resistance. Several mechanisms may explain the relation between insulin resistance and inflammatory factors, such as the hypersecretion of proinflammatory cytokines like interleukin-6 and tissue necrosis factor-Î, from adipose tissue. These cytokines exert stimulatory effects on the synthesis of acute phase proteins.

Though inflammation has such an importance in atherosclerosis, leucocytes which are integral part of inflammatory process, are not studied intensively. Hence, we studied leukocytic hydrolytic enzymes in CHD, which may have significant role in the inflammatory aspect of atherosclerosis and consequently in cardiovascular diseases.

MATERIALS AND METHODS

Materials

Micrococcus lysodeikticus and lysozyme standard were purchased from Sigma Chemicals Co, USA. N-Succinyl-L-Alanyl-L-Alanyl-L-Prolyl-L-Phenylalanine-4-nitroanilide (substrate for cathepsin G) was obtained from Fluka laboratories, USA. P-nitrophenyl phosphate and reduced glutathione were obtained from Sisco Co. All other chemicals and solvents used were of analytical reagent grade and obtained locally.

Patients

166 patients, [139(84%) men and 27(16%) women] with the diagnosis of AMI or unstable angina, registered in our hospital between January 2002 and December 2004 were selected for study. The diagnosis of AMI was established according to clinical criteria: chest pain, which lasted for up to 3 hours, ECG changes (ST elevation of 2 mm or more in at least two leads) and CK elevation. The diagnosis of hypertension was based on previous history of hypertension or systolic blood pressure > 140 mm of Hg and diastolic blood pressure > 90 mm of Hg on minimum two measurements. The diagnosis of diabetes was based on previous history of diabetes mellitus or fasting blood sugar more than 126 mg/dl or random blood sugar more than 200 mg/dl. All the diabetic CHD patients included in the study (80) were on oral hypoglycemic agents. A person was considered smoker or alcoholic based on his history of smoking or alcohol consumption. The control group consisted of 45 healthy, age-matched subjects, 21 men and 24 women, recruited from an annual check-up program. Age of patients and control subjects were between 25-50 years.

Inclusion criteria

Patients below 50 years of age, with diagnosis of angina or AMI and free from any kidney or liver diseases.
Exclusion criteria
Patients above 50 years of age, with any kidney or liver diseases and pregnancy.

Ethics committee of our hospital gave approval and informed consent was obtained from every patient.

Isolation of leukocytes
Samples were collected after overnight fasting in EDTA bulbs and leucocytes were isolated by established procedure.\textsuperscript{[3]} 5.0 ml of anticoagulated blood was mixed with 1.0 ml of freshly prepared 5% dextran solution and allowed to stand for 45 minutes. Supernatant was removed and centrifuged at 500 rpm for 10 min. in cold condition. Leukocyte pellet obtained was mixed with 1.5 ml ice-cold distilled water and then 1.5 ml ice-cold 1.8% NaCl solution and centrifuged at 500 rpm for 10 min. in cold condition. Isolated leukocyte pellet was suspended in one ml of ice-cold normal saline.

Leukocytic enzymes determination
Leukocyte pellet with ice-cold saline was transferred to a smooth walled homogenizing vessel and disrupted with a loose fitting motor driven Teflon pestle with 10 strokes. The homogenate was centrifuged at 3000 RPM for 10 min and supernatant was used for the hydrolytic enzymes estimation.

Acid phosphatase activity was determined by its action on p-nitrophenyl phosphate, which results in release of p-nitrophenol which is then quantified at 405 nm.\textsuperscript{[4]} Results were expressed as units/mg of protein.

The assay of lysozyme was based on the lysis of \textit{Micrococcus lysodeikticus} cells by lysozyme, which causes decrease in absorbance of substrate at 450 nm.\textsuperscript{[7]} In a substrate containing \textit{Micrococcus lysodeikticus}, sample or standard was added and readings were taken at 30 seconds and 10 minutes. Difference between two readings is calculated. Results were expressed as µg/mg of protein.

Adenosine deaminase (ADA) activity was estimated by its action on substrate containing adenosine. Principle of reaction is Berthlot reaction. Readings were taken at 640 nm. 1 unit of activity corresponds to the amount which liberates 1 µg of ammonia nitrogen/ml of sample/hour at 37°C.\textsuperscript{[8]} Results were expressed as units/mg of protein.

Cathepsin-G activity was determined by hydrolysis of substrate (N-Succinyl-L-Alanyl-L-Alanyl-L-Prolyl-L-Phenylalanine-4-nitroanilide) by cathepsin-G.\textsuperscript{[9]} In a cuvette, substrate and sample were mixed at 50°C. Amount of p-Nitrophenol liberated was measured at 410 nm. Results were expressed as units/mg of protein.

Protein estimation was carried out according to Lowry \textit{et al} with crystalline bovine serum albumin as standard. Sample was allowed to react with Folin-Ciocalteu reagent, taking reading at 660 nm.\textsuperscript{[9]} Results were expressed as mg/ml.

MDA\textsuperscript{[11]} levels were determined by their reaction with 2-Thiobarbituric acid (TBA). Protein were precipitated by adding 40% trichloroacetic acid and then 0.67% TBA was added. Mixture was boiled for 60 minutes.

Pink colour developed was extracted in n-butanol and read at 533 nm. 1.1, 3,3-Tetramethoxy propane was used as a standard. Results were expressed as µM/l.

GSH levels were estimated by reaction with 5, 5’-dithio-bis-(2-nitrobenzoic acid) (DTNB).\textsuperscript{[12]} Proteins were precipitated from blood by adding a reagent containing sodium chloride, EDTA and meta-phosphoric acid. Mixture was filtered and filtrate was allowed to react with DTNB. Yellow colour developed was read at 412 nm. A standard was included in the test. Results were expressed as µM/l.

GHB\textsuperscript{[13]} levels were determined by their reaction with TBA. Red blood cells were thoroughly washed with saline and then hydrolyzed with oxalic acid (i.e., hydrolysis of hexoses bound to hemoglobin whereby 5-hydroxymethyl furfural is liberated. After precipitating proteins, the supernatant was allowed to react with TBA at 37°C for 40 min. The yellow colored TBA - 5 - hydroxymethyl furfural adduct formed was measured at 443 nm in a spectrophotometer. Results were expressed as % of total hemoglobin.

Glucose levels were determined by GOD-POD method using kit supplied by Accurex, India.

Statistical analysis
The data from patients and controls were compared using unpaired student’s t-test and values were expressed as means ± standard deviation (SD). Correlation analysis was done by using Pearson correlation method. Sigma stat version 3.0 was used for statistical analysis.

RESULTS

General characteristics of CHD patients and controls are shown in Table 1. The table shows that age of CHD patients was less than 50 years. Percentage of male CHD patients was more than female CHD patients. The table shows higher BMI and waist to hip ratio in patients as compared to controls, marking importance of obesity in CHD patients, though elevation is not significant. Systolic and diastolic blood pressures (B.P) were increased in CHD patients than in controls. Number of hypertensive patients were in more diabetics.

Table 2 shows activities of 4 different hydrolases of leukocytes in CHD patients as compared to control subjects. Acid phosphatase and lysozyme values were significantly higher in CHD patients, as compared with controls \textit{(P}<0.001). ADA values were significantly high in diabetic CHD patients \textit{(P}<0.001). Cathepsin-G values were significantly low in CHD patients \textit{(P}<0.001).

Table 3 shows metabolic parameters in CHD patients and controls. MDA levels were significantly higher while GSH levels were significantly lower in diabetic as well as non-diabetic patient group \textit{(P}<0.001). Glucose and GHB levels were significantly higher in diabetic CHD patients \textit{(P}<0.001).

Table 4 shows correlation analysis between different parameters in the patients groups. Leukocyte acid phosphatase, lysozyme and ADA levels were found to be positively correlated and cathepsin G activity was negatively correlated with MDA, a lipid...
peroxidation product. Also, Leukocyte acid phosphatase, lysozyme and ADA activities were negatively correlated and cathepsin G activity was positively correlated with GSH, a well known antioxidant.

**DISCUSSION**

The root cause of CHD is mainly atherosclerosis. Inflammation, oxidative stress, antioxidants and leukocytic hydrolases has important role in pathology of atherosclerosis. Yoshikawa et al found that the increase in lipid peroxide causes the instability of lysosomal membranes and releases various kinds of hydrolytic enzymes, which can lead to further cell damage.[14]

In our study, we found significant increase in leukocyte hydrolytic enzymes, namely acid phosphatase, ADA and lysozyme, in patient group, suggesting their role in inflammation involved in CHD. We also found significant decrease in leukocyte cathepsin G activity, indicating anti-inflammatory role of this enzyme.

**Acid phosphatase**

Acid phosphatase (EC 3.1.3.2) is a marker enzyme, used for the study of lysosomal enzyme activity.[15] Acid phosphatase activity is found in monocytes, lymphocytes and neutrophils.

In our study, we found significantly higher activity of acid phosphatase in leukocytes of CHD patients than that of control subjects, which suggests that at least some hydrolytic enzymes are abnormally active in CHD and atherosclerosis.

Hoen et al found that in chronic vitamin C deficiency, lysosomal acid phosphatase activity was increased.[16] Leveille et al found that the activity of lysosomal acid phosphatase was significantly elevated in animals on low vitamin C diet, which indicated an inverse relationship between vitamin C concentrations and lysosomal enzyme activities.[17] In our study, leukocyte acid phosphatase was positively correlated with MDA and negatively correlated with GSH, confirming results of above studies.

**Lysozyme**

Lysozyme (EC 3.2.1.17) catalyzes the hydrolysis of polysaccharide chains that form structural elements of bacterial cell walls.

Significant rise in lysozyme activity (P<0.001) in patient group as compared to controls, suggests that lysozyme may be involved in inflammatory process in conjunction with unstable angina and AMI. Increased lysozyme activity may be considered as a part of systemic inflammatory response, as suggested by previous work of Hickey et al.[18] This was supported by our findings that lysozyme was positively correlated with MDA

---

**Table 4: Correlation analysis of different parameters in coronary heart disease group**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Parameters</th>
<th>Correlation coefficient (r)</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic angina</td>
<td>GSH Vs Acid phosphatase</td>
<td>-0.73</td>
<td>-0.88 to -0.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>GSH Vs Lysozyme</td>
<td>-0.73</td>
<td>-0.88 to -0.45</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>GSH Vs ADA</td>
<td>-0.68</td>
<td>-0.86 to -0.36</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>GSH Vs Cathepsin G</td>
<td>-0.76</td>
<td>-0.86 to -0.34</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>MDA Vs Lysozyme</td>
<td>0.44</td>
<td>0.30 to 0.57</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>MDA Vs ADA</td>
<td>0.76</td>
<td>0.50 to 0.90</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>MDA Vs Cathepsin G</td>
<td>0.73</td>
<td>0.51 to 0.90</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetic AMI</td>
<td>GSH Vs Acid phosphatase</td>
<td>0.55</td>
<td>-0.71 to -0.34</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>GSH Vs ADA</td>
<td>0.52</td>
<td>-0.68 to -0.23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>MDA Vs Acid phosphatase</td>
<td>0.67</td>
<td>-0.49 to -0.79</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Table 3: Metabolic parameters in coronary heart disease patients as compared with controls**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>Acute myocardial infarction</th>
<th>Unstable angina</th>
<th>DM</th>
<th>DMD</th>
<th>ZND</th>
<th>DM</th>
<th>DND</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>45</td>
<td>58</td>
<td>48</td>
<td>22</td>
<td>38</td>
<td>81</td>
<td>22</td>
<td>38</td>
</tr>
<tr>
<td>DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA μM/l</td>
<td>Mean ± SD 95% CI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2±0.1</td>
<td>4.6±0.9</td>
<td>4.4±0.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSH μM/l</td>
<td>Mean ± SD 95% CI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2±0.1</td>
<td>2.0±0.1</td>
<td>1.8±0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose mg/dl</td>
<td>Mean ± SD 95% CI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>162±44</td>
<td>162±44</td>
<td>162±44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GHB % of total</td>
<td>Mean ± SD 95% CI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10±1.7</td>
<td>10±1.7</td>
<td>10±1.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2: Hydrololytic enzymes of leucocytes in coronary heart disease patients and controls**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>Acute myocardial infarction</th>
<th>Unstable angina</th>
<th>DM</th>
<th>DMD</th>
<th>ZND</th>
<th>DM</th>
<th>DND</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>45</td>
<td>58</td>
<td>48</td>
<td>22</td>
<td>38</td>
<td>81</td>
<td>22</td>
<td>38</td>
</tr>
<tr>
<td>Degree of freedom</td>
<td>Mean ± SD 95% CI</td>
<td>Mean ± SD 95% CI</td>
<td>Mean ± SD 95% CI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acid phosphatase</td>
<td>Units/mg protein</td>
<td>2.2±0.1</td>
<td>4.6±0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lysozyme/mg protein</td>
<td>2.2±0.1</td>
<td>4.6±0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADA units/mg protein</td>
<td>2.2±0.1</td>
<td>4.6±0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cathepsin G units/mg protein</td>
<td>2.2±0.1</td>
<td>4.6±0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 1: Demographic data of coronary heart disease patients and controls**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>Acute myocardial infarction</th>
<th>Angina</th>
<th>Diabetic Non-diabetic</th>
<th>Angina</th>
<th>Diabetic Non-diabetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>45</td>
<td>58</td>
<td>48</td>
<td>22</td>
<td>38</td>
<td>81</td>
</tr>
<tr>
<td>Age (years)</td>
<td>43 (13)</td>
<td>46±10</td>
<td>42±10</td>
<td>48±10</td>
<td>42±7</td>
<td>88±34</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>78±44</td>
<td>90±21</td>
<td>77±17</td>
<td>98±43</td>
<td>76±14</td>
<td>92±30</td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>Mean ± SD 95% CI</td>
<td>56±17</td>
<td>65±11</td>
<td>64±13</td>
<td>65±12</td>
<td>64±8</td>
</tr>
<tr>
<td>Body mass index</td>
<td>Mean ± SD 95% CI</td>
<td>22.5±2.6</td>
<td>25.3±4.5</td>
<td>24.7±5.1</td>
<td>25.4±4</td>
<td>25.0±4</td>
</tr>
<tr>
<td>Waist hip</td>
<td>Mean ± SD 95% CI</td>
<td>89±06</td>
<td>1.00±0.09</td>
<td>1.05±0.14</td>
<td>1.09±0.14</td>
<td>0.99±0.08</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Mean ± SD 95% CI</td>
<td>115±6</td>
<td>137±18</td>
<td>130±22</td>
<td>143±15</td>
<td>135±19</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Mean ± SD 95% CI</td>
<td>81±3</td>
<td>95±10</td>
<td>87±13</td>
<td>95±9</td>
<td>86±11</td>
</tr>
<tr>
<td>Hypertensive (%)</td>
<td>Mean ± SD 95% CI</td>
<td>0</td>
<td>41±24</td>
<td>29±14</td>
<td>50±11</td>
<td>24±9</td>
</tr>
<tr>
<td>Smokers (%)</td>
<td>Mean ± SD 95% CI</td>
<td>0</td>
<td>48±28</td>
<td>65±31</td>
<td>45±10</td>
<td>37±14</td>
</tr>
<tr>
<td>Alcoholic (%)</td>
<td>Mean ± SD 95% CI</td>
<td>0</td>
<td>43±25</td>
<td>63±30</td>
<td>41±9</td>
<td>45±17</td>
</tr>
</tbody>
</table>

and negatively correlated with GSH.

Adenosine deaminase (ADA)
ADA (EC 3.5.4.4) catalyzes the conversion of adenosine to inosine and 2'-deoxyadenosine to 2'-deoxynosine. The major source of serum ADA may be lymphocytes or the monocyte-macrophage cell system. It was reported that elevated levels of ADA reflect the changes in the immune response in the pathogenesis of atherosclerosis and CHD. Hence ADA can be considered as important marker in assessing CHD.[19] Also, ADA is considered as an inflammatory marker in rheumatoid arthritis[20] and in the mouse model of pleurisy.[21]

In our study, we found significantly elevated leukocyte ADA levels in CHD patients, which is similar to work of Kopff et al, who found that plasma ADA activity is increased in patients with unstable angina.[22] Positive correlation found between leukocyte ADA and MDA as well as negative correlation with GSH suggest that ADA may serve as an indicator of underlying inflammation.

Cathepsin-G
Our results showed significantly lower values of cathepsin G in patient group (P<0.001) and decrease was more pronounced in diabetic CHD group. This indicates that cathepsin G level is susceptible to glucose control. In our study, cathepsin G was negatively correlated with MDA and positively correlated with GSH. This indicates that cathepsin G is susceptible to oxidative stress status.

GSH is a well known antioxidant, negative correlation with acid phosphatase, lysozyme and adenosine deaminase indicate possible inflammatory role of these hydrolases in CHD, at least in diabetic CHD. Similarly, MDA is a well known lipid peroxidation product. Hence, positive correlation suggested possible role of these hydrolases in oxidative stress, at least in diabetic CHD condition. This also indicates that these hydrolases are more active in diabetic CHD patients. Also, positive correlation of cathepsin G with GSH and negative correlation with MDA, suggests possible anti-inflammatory role of cathepsin G.

Studies by Bank et al in 1999 and 2000 showed that cathepsin-G inactivates interleukin-6 at the site of inflammation.[24,25] Both bradykinin and interleukin-6 are well-known inflammatory mediators. Thus it may be possible that cathepsin-G can act as an anti-inflammatory molecule. Another possibility is that cathepsin-G may be consumed during the complex interactions between different enzymes, during the inflammatory process. Shao B et al demonstrated that oxidants from leukocytes inactivate cathepsin-G.[26]

Effect of various factors
No significant difference was found between results of male patients and female patients, suggesting that gender don’t have significant effect on leukocyte hydrolase activity. Hypertension, smoking, BMI are important confounding factors, but results were more or less similar after adjusting for these important parameters. Increase in acid phosphatase activity is mostly considered with prostate cancer, but none of our CHD patients had any abnormality of prostate gland, as indicated by through medical history.

Medications given to patients may affect the results. Many patients are thrombolyzed and treated with heparin and aspirin. It was shown that heparin have anti-inflammatory effect and may affect leukocyte function.[27] Similarly, it is known that after AMI, aspirin is associated with lower levels of inflammatory markers.[28]

Strengths and limitations of study and future research directions
This study suggests a relatively new approach to CHD. Hydrolytic enzymes of leukocytes, which are poorly studied in CHD patients, provide new insights in the role of leukocytes in CHD. These enzymes can be used as measures of inflammation associated with CHD and can be beneficial to patient’s care, when controlled. Adanin et al suggested that inhibition of ADA might be a novel and viable therapeutic approach to manage the systemic inflammatory response.[29]

But, as number of samples is less in our study, extensive studies with larger number of samples are needed to confirm exact role of these enzymes. Also, study of different cell lines of leukocytes (neutrophils, monocytes etc) and their enzymes may provide a detailed view of still unexplored area of CHD and atherosclerosis.

CONCLUSION
Our study indicates possible inflammatory role of leukocyte hydrolytic enzymes, mainly acid phosphatase, lysozyme and adenosine deaminase and anti-inflammatory role of cathepsin-G. In conclusion, it is possible that inflammation, oxidative stress and diabetes have profound effect on internal environment of leukocytes, which causes disturbed balance between hydrolytic enzymes, which may have significant role in atherosclerosis and CHD.

REFERENCES
4. Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors.

Source of Support: Nil, Conflict of Interest: None declared.

Author Help: Online Submission of the Manuscripts

Articles can be submitted online from http://www.jurnalinfo.com. For online submission articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:
Prepare the title page, covering letter, acknowledgement, etc., using a word processor program. All information which can reveal your identity should be here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article file:
The main text of the article, beginning from Abstract till References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers, etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 400 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file.

3) Images:
Submit good quality colour images. Each image should be less than 100 kb in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 3 inches) or by reducing the quality of image. All image formats (jpeg, tiff, gif, bmp, png, eps, etc.) are acceptable; jpeg is most suitable. The image quality should be good enough to judge the scientific value of the image. Always retain a good quality, high resolution image for print purpose. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:
Legends for the figures/images should be included at the end of the article file.